-

10:07:54 PM

OCGN Stock News

OCGN - Ocugen Inc

06/21/22 7:00 AM

Nasdaq : OCGN

covid-19high short

Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases

Ocugen, Inc. (NASDAQ:

RHEA-AI

neutral

06/14/22 7:00 AM

Nasdaq : OCGN

high short

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

Ocugen , Inc . (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among

RHEA-AI

very positive

06/13/22 7:00 AM

Nasdaq : OCGN

high short

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy

Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene

RHEA-AI

neutral

06/09/22 6:17 PM

Nasdaq : OCGN

conferenceshigh short

Ocugen, Inc. to Present at BIO International Convention 2022

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen’s Senior Vice President, Commercial, will

RHEA-AI

neutral

05/24/22 7:11 AM

Nasdaq : OCGN

high short

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and

RHEA-AI

neutral

05/23/22 7:34 AM

Nasdaq : OCGN

conferenceshigh short

Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, will

RHEA-AI

neutral

05/23/22 6:36 AM

Nasdaq : OCGN

clinical trialhigh short

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that the U.S. Food and Drug Administration

RHEA-AI

neutral

05/06/22 6:33 AM

Nasdaq : OCGN

earningshigh short

Ocugen Provides Business Update and First Quarter 2022 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review Ocugen’s exclusive territory for COVAXIN™ (BBV152) marketing expanded to include

RHEA-AI

neutral

05/02/22 7:37 AM

Nasdaq : OCGN

conferencesearningshigh short

Ocugen to Host Conference Call on Friday, May 6 at 8:30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced that it will host a conference call to provide a business update and discuss

RHEA-AI

neutral

04/29/22 11:36 AM

Nasdaq : OCGN

conferencesclinical trialhigh short

Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the development of a

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

OCGN Data

Websiteocugen.com
CeoShankar Musunuri
Security nameOcugen Inc
Issue typecs
Sic code3842
Employees15
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Sanitary Paper Product Manufacturing
Address5 Great Valley Pkwy Ste 160
StatePennsylvania
CityMalvern
Zip19355
CountryUS
Phone14843284698

About Ocugen Inc

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug - "one to many" and its novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The Company is co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. market.